Association of GST null genotypes with anti-tuberculosis drug induced hepatotoxicity in Western Indian population

Annals of Hepatology

Volumn 12, Issue 6, 2013, Pages 959-965

  Gupta, Vinod H ^a   Singh, Meenakshi ^a   Amarapurkar, Deepak N ^b   Sasi, Preetha ^a   Joshi, Jyotsna M ^c   Baijal, Rajiv ^d   Praveen Kumar, K H R ^d   Amarapurkar, Anjali D ^c   Joshi, Kalpana ^e   Wangikar, Pramod P ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

^b BOMBAY HOSPITAL   (India)

^c BYL NAIR CHARITABLE HOSPITAL   (India)

^d Jagjivanram Western Railway Hospital   (India)

^e SYMBIOSIS INTERNATIONAL DEEMED UNIVERSITY   (India)

Author keywords

Case control study; Drug induced hepatotoxicity; Homozygous null mutation; Phase II enzymes

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ETHAMBUTOL; GLUTATHIONE TRANSFERASE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FAMILIAL DISEASE; FEMALE; GENE; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GSTM1 GENE; GSTT1 GENE; HUMAN; INDIAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TUBERCULOSIS; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HOMOZYGOTE; HUMANS; INDIA; MALE; MIDDLE AGED; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84890063567     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31302-x     Document Type: Article

References (43)

1. WHO. Global tuberculosis control 2011. Geneva, Switzerland 2011. Available from: http://wwwwhoint/tb/publications/global_report/2011/gtbr11_fullpdf
2. Timbrell JA, Wright JM, Baillie TA. Monoacetylhydrazine as a metabolite of isoniazid in man. Clin Pharmacol Ther 1977; 22: 602-8.
3. Singh M, Sasi P, Rai G, Gupta VH, Amarapurkar D, Wangikar PP. Studies on toxicity of antitubercular drugs namely isoniazid, rifampicin, and pyrazinamide in an in vitro model of HepG2 cell line. Medicinal Chemistry Research 2011; 20: 1611-5.
4. Agal S, Baijal R, Pramanik S, Patel N, Gupte P, Kamani P, Amarapurkar D. Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol 2005; 20: 1745-52.
5. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99: 465-71.
6. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008; 23: 192-202.
7. Sun F, Chen Y, Xiang Y, Zhan S. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2008; 12: 994-1002.
8. Simon T, Becquemont L, Mary-Krause M, de Waziers I, Beaune P, Funck-Brentano C, Jaillon P. Combined glutathione- S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther 2000; 67: 432-7.
9. Strange RC, Jones PW, Fryer AA. Glutathione S-transferase: genetics and role in toxicology. Toxicol Lett 2000; 112: 357-63.
10. Nelson SD, Mitchell JR, Timbrell JA, Snodgrass WR, Corcoran GB. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science 1976; 193: 901-3.
11. Bose PD, Sarma MP, Medhi S, Das BC, Husain SA, Kar P. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol 2011; 26: 312-8.
12. Gupta VH, Amarapurkar DN, Singh M, Sasi P, Joshi JM, Baijal R, Praveen Kumar HR, et al. Association of NAT2 and CYP2E1 gene polymorphisms with antituberculosis drug induced hepatotoxicity in Western India. J Gastro Hepatol 2013. Accepted manuscript online: 11 mar 2013. DOI: 10.1111/jgh.12194.
13. Lv X, Tang S, Xia Y, Zhang Y, Wu S, Yang Z, Li X, et al. NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population. Ann Hepatol 2012; 11: 700-7.
14. Teixeira RL, Morato RG, Cabello PH, Muniz LM, Moreira Ada S, Kritski AL, Mello FC, et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz 2011; 106: 716-24.
15. Andreoli SP, Mallett CP, Bergstein JM. Role of glutathione in protecting endothelial cells against hydrogen peroxide oxidant injury. J Lab Clin Med 1986; 108: 190-8.
16. Meister A. Selective modification of glutathione metabolism. Science 1983; 220: 472-7.
17. Hussey AJ, Stockman PK, Beckett GJ, Hayes JD. Variations in the glutathione S-transferase subunits expressed in human livers. Biochim Biophys Acta 1986; 874: 1-12.
18. Meyer DJ, Coles B, Pemble SE, Gilmore KS, Fraser GM, Ketterer B. Theta, a new class of glutathione transferases purified from rat and man. Biochem J 1991; 274: 409-14.
19. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, B. Ketterer, et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994; 300: 271-6.
20. Roy B, Chowdhury A, Kundu S, Santra A, Dey B, Chakraborty M, Majumder PP. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol 2001; 16: 1033-7.
21. Huang YS, Su WJ, Huang YH, Chen CY, Chang FY, Lin HC, Lee SD. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007; 47: 128-34.
22. Chatterjee S, Lyle N, Mandal A, Kundu S. GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs. J Clin Pharm Ther 2010; 35: 465-70.
23. Leiro V, Fernandez VA, Valverde D, Constenla L, Vazquez R, Pineiro L, Gonzalez QA. Influence of glutathione Stransferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int 2008; 28: 835-9.
24. Tang SW, Lv XZ, Zhang Y, Wu SS, Yang ZR, Xia YY, Tu DH, et al. CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study. J Clin Pharm Ther 2012; 37: 588-93.
25. Malhotra KC. Morphological composition of the people of India. J Human Evolution 1978; 7: 45-53.
26. Shephard DA. The 1975 Declaration of Helsinki and consent. Can Med Assoc J 1976; 115: 1191-2.
27. WHO.Treatment of tuberculosis. Guidelines for National Programmes. 3rd ed.Geneva: World Health Organization 2003; WHO/CD5/TB 2003.313.
28. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11: 272-6.
29. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
30. Arand M, Muhlbauer R, Hengstler J, Jager E, Fuchs J, Winkler L, Oesch F. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem 1996; 236: 184-6.
31. R Development Core Team. R: A language and environment for statistical computing 2011; Vienna, Austria. ISBN 3- 900051-07-0, URL: http://wwwatsuclaedu/stat/r/dac/logithtml
32. Bolt HM, Their R. Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology. Curr Drug Metab 2006; 7: 613-28.
33. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, Baranova H, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001; 10: 1239-48.
34. Seidegard J, Ekstrom G. The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. Environ Health Perspect 1997; 105: 791-9.
35. Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, Hayakawa A, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet 2007; 52: 166-71.
36. Li C, Long J, Hu X, Zhou Y. GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis. Eur J Clin Microbiol Infect Dis 2013. Doi 10.1007/s10096- 013-1831-y.
37. Cai Y, Yi J, Zhou C, Shen X. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS One 2012; 7. Doi: 10.1371/ journal.pone.0047769.
38. Tang N, Deng R, Wang Y, Lin M, Li H, Qiu Y, Hong M, et al. GSTM1 and GSTT1 null polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2013; 17: 17-25.
39. Kim SH, Yoon HJ, Shin DH, Park SS, Kim YS, Park JS, Jee YK. GSTT1 and GSTM1 null mutations and adverse reactions induced by anti-tuberculosis drugs in Koreans. Tuberculosis (Edinb) 2010; 90: 39-43.
40. Monteiro TP, El-Jaick KB, Jeovanio-Silva AL, Brasil PE, Costa MJ, Rolla VC, de Castro L. The roles of GSTM1 and GSTT1 null genotypes and other predictors in antituberculosis drug-induced liver injury. J Clin Pharm Ther 2012; 37: 712-8.
41. Haase D, Binder C, Bunger J, Fonatsch C, Streubel B, Schnittger S, Griesinger F, et al. Increased risk for therapyassociated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1. Leuk Res 2002; 26: 249-54.
42. Voso MT, D'Alo F, Putzulu R, Mele L, Scardocci A, Chiusolo P, Latagliata R, et al. Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood 2002; 100: 2703-7.
43. Awasthi YC, Sharma R, Singhal SS. Human glutathione Stransferases. Int J Biochem 1994; 26: 295.